Navigation Links
Ambit Biosciences Completes $50 Million Financing to Advance Lead Drug Candidate in Acute Myeloid Leukemia
Date:11/6/2012

SAN DIEGO, Nov. 6, 2012 /PRNewswire/ -- Ambit Biosciences Inc. today announced that the company has closed the first $25 million tranche of a new $50 million preferred stock financing to support continued advancement of its lead drug candidate, quizartinib.  Existing investor OrbiMed Advisors led the financing with participation from other existing Ambit investors including Aisling Capital, Apposite Healthcare, Roche Ventures, GrowthWorks, MedImmune Ventures, Forward Ventures, GIMV, and Radius Ventures. 

"2012 has been a pivotal year of progress for Ambit, and this financing is a reflection of that progress and the momentum we have built as a team," said Michael Martino, President and CEO of Ambit. "We've received the data from our large, 333 patient Phase 2 trial of quizartinib in patients with relapsed/refractory AML, and we are excited to present that data at ASH in Atlanta in December. We've refocused and prioritized our work on earlier stage pipeline assets, including our oral JAK2 and CSF1R inhibitor programs, and re-energized the team. This financing, with OrbiMed Advisors leading a round in which all existing investors participated, is a strong vote of confidence in our direction and provides the resources to accelerate our progress in 2013.""  

In conjunction with the financing, David Bonita, M.D, of OrbiMed Advisors will join Ambit's board of directors.

"Ambit's new management team has impressed us with its focus on moving the company's core clinical programs forward in clinical development," said Dr. Bonita. "We believe that the recent data from its 333 patient Phase 2 trial in relapsed and refractory acute myeloid leukemia are very promising and look forward to working with the management team and their clinical collaborators in moving quizartinib through clinical development and into clinical use by physicians."

About Ambit Biosciences
Ambit Biosciences is a privately held biopharmaceutical compa
'/>"/>

SOURCE Ambit Biosciences Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Ambit Biosciences and Teva Announce Clearance of an Investigational New Drug (IND) Application for CEP-32496, A Novel BRAF(V600E) Inhibitor
2. Pressure BioSciences, Inc. and Target Discovery, Inc. Expand Strategic License Agreement and Collaboration Supporting TDIs Planned Offering of Personalized Medicine Clinical Diagnostic Services
3. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2012 Financial Results
4. Amarantus BioSciences to Present at the New York Biotechnology Association (NYBA) 21st Annual Meeting on May 2nd, 2012
5. Neurocrine Biosciences Reports First Quarter 2012 Results
6. Pressure BioSciences, Inc. to Discuss First Quarter 2012 Financial Results And Provide Business Update
7. Neurocrine Biosciences to Present at the Jefferies 2012 Global Healthcare Conference
8. 3-V Biosciences To Present at the Seventh Annual JMP Securities Healthcare Conference
9. Sofie Biosciences receives $1M Phase II SBIR grant from the DOE
10. Frost & Sullivan 2012 New Product Innovation in Bioanalytics Awarded to Protea Biosciences
11. Pressure BioSciences Patented PCT Platform Shown to Significantly Improve Protein and DNA Detection in Multiple Studies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2015)... , Sept. 2, 2015  The report on breast ... of breast cancer drugs on the basis of the ... originates from the inner lining of milk ducts or ... malignant type of tumor that can spread to other ... which starts in lobules is referred as lobular carcinoma, ...
(Date:9/2/2015)... LONDON , Sept. 2, 2015 ... coil is used to treat an unruptured and ... artery wall). The treatment is either known as ... procedure, the endovascular coil blocks the blood flow ... usually performed under general anaesthesia by an interventional ...
(Date:9/2/2015)...  Array BioPharma Inc. (Nasdaq: ARRY ) ... Ron Squarer , will present at the Wells ... is welcome to participate in the conference through ... Fargo Securities Healthcare ConferencePresenter: Ron Squarer, Chief Executive ... a.m. Eastern Time Webcast: www.arraybiopharma.com   ...
Breaking Medicine Technology:Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 2Breast Cancer Therapeutics: Pipeline Analysis Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2015 - 2023 3Global Neuroendovascular Coil Market 2015-2019 2
... LOS ANGELES, Oct. 24, 2011 NeuroSigma, Inc., a ... has signed a contract with the University of California, ... clinical trial to study the use of non-invasive, external ... Deficit Hyperactivity Disorder (ADHD).  NeuroSigma is the exclusive worldwide ...
... HealthWarehouse.com, Inc. (OTC: HEWA), a leading VIPPS-accredited ... begin providing prescription medications for WhiteGlove Health, Inc., ... excited to have a national partner to provide ... Robert Fabbio, co-founder and chief executive officer of ...
Cached Medicine Technology:NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD 2NeuroSigma Funds First-Ever Pediatric Clinical Trial to Study Non-Invasive External Trigeminal Nerve Stimulation for the Treatment of ADHD 3WhiteGlove Health Selects HealthWarehouse.com to Provide Prescription Medications to its Members Nationwide 2
(Date:9/2/2015)... ... September 02, 2015 , ... Alameda County Community Food ... Action Month” during the entire month of September. In the spirit of ... its efforts this September to an awareness campaign educating legislators and the public ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... ... Cancer Center at Children's Healthcare of Atlanta to help support childhood cancer ... discuss the upcoming WSB Radio Care-A-Thon , which is the fund-raising event ...
(Date:9/2/2015)... ... September 02, 2015 , ... Medical ... has completed a recapitalization with new investment partners Beecken Petty O’Keefe & ... each offer extensive expertise and connections within the healthcare industry, which makes ...
(Date:9/2/2015)... (PRWEB) , ... September 02, 2015 , ... Every year ... it; others dread it. However, few are prepared to face the academic workload confronting ... starts. Our schools haven’t prepared them since schools don’t teach students how to study. ...
(Date:9/2/2015)... Destin, Florida (PRWEB) , ... September 02, 2015 , ... ... in drug prices over the past year and its negative impact on consumers. It ... regular prescription medication and 10% were paying as much as an extra $100 compared ...
Breaking Medicine News(10 mins):Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 2Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 3Health News:#IfOnlyYouKnew: Alameda County Community Food Bank Commemorates September as National Hunger Action Month 4Health News:DoMyOwnPestControl.com Goes Gold for Childhood Cancer Awareness Month 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 2Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 3Health News:Medical Solutions Completes Recapitalization with Beecken Petty O’Keefe & Company and Heritage Group 4Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 2Health News:5 Essential Study Tips Every Student Needs for Academic Success but Schools Do Not Teach 3Health News:Watertree Health President Responds to Consumer Reports Survey on Rising Prescription Drug Prices 2
... says hazard isn,t proven, , SATURDAY, Sept. 5 (HealthDay ... (pronounced THAL ates) are nearly ubiquitous in consumer products, ... plastics and toys. , A little over a decade ... began to focus on phthalates and have been working ...
... , ST. LOUIS, Sept, 4 KV ... Thomas McHugh, the Vice President of Finance and Corporate Controller of ... Mr. McHugh replaces Ronald J. Kanterman, who ceased serving as ... Mr. Kanterman continues to serve as a member of the ...
... NEWPORT BEACH, Calif., Sept. 4 Nationwide Health Properties ... Portfolio Officer, Abdo Khoury, will participate on a healthcare real estate ... Conference on Friday, September 11, 2009 beginning at 7:30 a.m. CDT. ... a live audio-webcast, please us the following link: ...
... University of Toronto have identified a protein which plays ... could enhance our understanding of how the brain works, ... of T graduate student John Calarco, working in the ... and Biomolecular Research, University of Toronto) and Prof. Mei ...
... major episode later, researchers say , FRIDAY, Sept. 4 ... to have major depression, anxiety disorders and eating disorders ... researchers interviewed 755 teenagers who were about age 16 ... substance abuse. , About 8 percent were found to ...
... ... ... American Pharmacists Association (APhA) is recommending that the public begin visiting their ... 80,000 pharmacists have been trained to administer immunizations and have the authority to administer ...
Cached Medicine News:Health News:In Toys and More, Are Chemicals Safe or Harmful? 2Health News:In Toys and More, Are Chemicals Safe or Harmful? 3Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 2Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 3Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 4Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 5Health News:KV Pharmaceutical Appoints Interim Chief Financial Officer 6Health News:U of T researchers identify protein 2Health News:Depressed Teens Continue to Suffer 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 2Health News:Pharmacists Urge the Public to Begin Getting Immunized 3
... System RCS 800 closes various plastic primary and ... way. Different tube heights and diameters can be ... be used for send-outs. The integration into other ... System RSD 800 and High Throughput Sorter RSD ...
... Decapping System DS 800 selectively removes closures from ... the barcode towards the rack opening in one ... integrated in PVT Systems like Sorting System RS ... Sorter RSD ProVolume and Aliquoting System RSD 800A. ...
... Nanogen offers reagents to detect ... human parainfluenza virus 1, 2 and ... and respiratory syncytial virus A and ... reagents to create homebrew tests., ...
... Alert Detection Reagents provide molecular labs a ... assays. By using our MGB technology, combined ... is now able to provide molecular labs ... sequences of specific organisms or genetic mutations ...
Medicine Products: